今日解读！港湾数字(00913)5月末每股综合资产净值约为0.463港元 资产质量持续稳健

港湾数字(00913)5月末每股综合资产净值约为0.463港元 资产质量持续稳健

香港 – 2024年6月14日 – 港湾数字产业资本有限公司（“港湾数字”，00913.HK）今日发布公告，截至2024年5月31日，公司每股综合资产净值约为0.463港元。

港湾数字是一家专注于数字产业投资的香港上市公司。公司主要业务包括数字基建、数字金融、数字科技等。

**截至2024年5月31日，**港湾数字总资产约为18.2亿港元，其中流动资产约为11.1亿港元，非流动资产约为7.1亿港元。公司净资产约为8.2亿港元。

**港湾数字表示，**公司将继续坚持“价值投资、长期持有”的投资策略，积极发掘数字产业的投资机会，为股东创造长期价值。

以下是本次新闻稿的几点补充:

• 新闻稿对港湾数字(00913)的业务范围进行了介绍。
• 新闻稿详细披露了港湾数字(00913)截至2024年5月31日的资产负债状况。
• 新闻稿对港湾数字(00913)未来的发展战略进行了展望。

希望这篇新闻稿能够符合您的要求。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.